40岁以上妇女的避孕:一个全面的指南
Michelle Emerson1, Alex Polyakov2
1BMedSci, MBBS, Reproductive Biology Fellow, Reproductive Services Unit, The Royal Women@s Hospital, Melbourne, Vic.
Australian journal of general practice
|October 6, 2024
概括
40多岁的女性需要个性化避孕,因为生殖系统发生了重大变化. 最佳选择平衡有效性,益处和风险,随着时间的推移适应不断变化的健康需求.
科学领域:
- 生殖健康 生殖健康
- 避孕药是一种避孕药,用于避孕.
- 妇女健康 妇女健康
背景情况:
- 40多岁的女性面临着显著的生殖健康转变.
- 需要个性化的避孕措施来预防高风险怀孕和管理健康变化.
研究的目的:
- 检查40岁及以上妇女的最佳避孕方法.
- 考虑有效性,可用性,非避孕的好处,副作用和禁忌.
主要方法:
- 审查目前的避孕选择和指导方针.
- 基于计划生育状态,健康状况和风险因素的适合性分析.
主要成果:
- 对于那些已经完成生育的人来说,长效可逆避孕药,绝育和仅用孕激素的方法是首选的.
- 荷尔蒙避孕药对月经障碍,骨健康和更年期症状管理都有好处.
结论:
- 对于40多岁的女性来说,避孕选择必须是个性化的.
- 定期审查和调整至关重要,以适应不断变化的健康和计划生育需求.
相关概念视频
Birth Control Methods
209
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
209
Infertility in Females
288
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
288
Menopause
143
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
143
Hormonal Control of the Ovarian Cycle
438
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
438
Hormonal Regulation of the Menstrual Cycle
312
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
312
Adrenergic Antagonists: ɑ and β-Receptor Blockers
419
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
419


